Titan Pharmaceuticals Inc (TTNP) - Total Assets
Based on the latest financial reports, Titan Pharmaceuticals Inc (TTNP) holds total assets worth $3.05 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Titan Pharmaceuticals Inc shareholders equity for net asset value and shareholders' equity analysis.
Titan Pharmaceuticals Inc - Total Assets Trend (1995–2024)
This chart illustrates how Titan Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Titan Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Titan Pharmaceuticals Inc's total assets of $3.05 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.9% |
| Accounts Receivable | $62.00K | 2.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2024)
This chart illustrates how Titan Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TTNP stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Titan Pharmaceuticals Inc's current assets represent 100.0% of total assets in 2024, an increase from 21.3% in 1995.
- Cash Position: Cash and equivalents constituted 96.9% of total assets in 2024, up from 19.2% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 2.1% of total assets.
Titan Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Titan Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Titan Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.60 | 12.22 | 1.13 |
| Quick Ratio | 11.60 | 12.22 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.79 Million | $3.99 Million | $772.00K |
Titan Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Titan Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.20 |
| Latest Market Cap to Assets Ratio | 2.10 |
| Asset Growth Rate (YoY) | -63.9% |
| Total Assets | $2.92 Million |
| Market Capitalization | $6.13 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Titan Pharmaceuticals Inc's assets at a significant premium (2.10x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Titan Pharmaceuticals Inc's assets decreased by 63.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Titan Pharmaceuticals Inc (1995–2024)
The table below shows the annual total assets of Titan Pharmaceuticals Inc from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.92 Million | -63.85% |
| 2023-12-31 | $8.09 Million | +99.26% |
| 2022-12-31 | $4.06 Million | -49.24% |
| 2021-12-31 | $7.99 Million | -1.15% |
| 2020-12-31 | $8.09 Million | -15.07% |
| 2019-12-31 | $9.52 Million | -32.44% |
| 2018-12-31 | $14.10 Million | +58.28% |
| 2017-12-31 | $8.90 Million | -52.30% |
| 2016-12-31 | $18.67 Million | +40.49% |
| 2015-12-31 | $13.29 Million | -36.28% |
| 2014-12-31 | $20.85 Million | +13.18% |
| 2013-12-31 | $18.42 Million | -25.79% |
| 2012-12-31 | $24.83 Million | +143.00% |
| 2011-12-31 | $10.22 Million | +115.00% |
| 2010-12-31 | $4.75 Million | +27.54% |
| 2009-12-31 | $3.73 Million | -34.63% |
| 2008-12-31 | $5.70 Million | -81.52% |
| 2007-12-31 | $30.84 Million | +105.08% |
| 2006-12-31 | $15.04 Million | -23.80% |
| 2005-12-31 | $19.74 Million | -48.90% |
| 2004-12-31 | $38.63 Million | -21.18% |
| 2003-12-31 | $49.01 Million | -35.45% |
| 2002-12-31 | $75.93 Million | -29.13% |
| 2001-12-31 | $107.13 Million | -9.55% |
| 2000-12-31 | $118.44 Million | +149.88% |
| 1999-12-31 | $47.40 Million | +288.52% |
| 1998-12-31 | $12.20 Million | -52.34% |
| 1997-12-31 | $25.60 Million | +56.10% |
| 1996-12-31 | $16.40 Million | +248.94% |
| 1995-12-31 | $4.70 Million | -- |
About Titan Pharmaceuticals Inc
As of October 1, 2025, Titan Pharmaceuticals, Inc. was acquired by KE Sdn Bhd, in a reverse merger transaction. Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.